局部晚期宫颈癌的免疫治疗：将 KEYNOTE-A18 纳入治疗策略。
Immunotherapy in locally advanced cervical cancer: Integrating KEYNOTE-A18 into management strategies.
机构信息
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
出版信息
Med. 2024 Jun 14;5(6):487-489. doi: 10.1016/j.medj.2024.05.001.
In locally advanced cervical cancer (LACC), the benefit of PD-1 blockade was unknown. In KEYNOTE-A18, Lorusso et al. compared the efficacy and safety of adding pembrolizumab to chemoradiation in LACC and demonstrated favorable outcomes. Given multiple approved indications of pembrolizumab in cervical cancer, strategies for optimal integration into management will be needed to maximize overall survival.
在局部晚期宫颈癌（LACC）中，PD-1 阻断的获益尚不明确。在 KEYNOTE-A18 研究中，Lorusso 等人比较了在 LACC 中添加 pembrolizumab 与放化疗联合的疗效和安全性，结果显示其具有良好的疗效。鉴于 pembrolizumab 在宫颈癌中有多种已获批的适应证，需要制定最佳的治疗策略将其纳入管理，以最大限度地提高总生存期。
Zotero 插件